Claims
- 1. A chemical compound selected from the group consisting of a compound having the formula ##STR66## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of phenyl, substituted phenyl and pyridinyl, wherein said substituted phenyl is phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl and nitro;
- n is an integer of from 2 to 6 inclusive, provided that when C.sub.n H.sub.2n represents a branched alkylene chain, then at least 2 carbon atoms are present in the linear portion of the chain linking
- B with the piperazine nitrogen atom; and
- B is a radical having the formula ##STR67## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and
- M is a member selected from the group consisting of phenyl, phenylmethyl, mercapto, lower alkylthio, amino, lower alkylcarbonylamino, lower alkyloxycarbonylamino, and cycloalkyl having from 3 to 6 carbon atoms.
- 2. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of a compound having the formula ##STR68## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of phenyl, substituted phenyl and pyridinyl, wherein said substituted phenyl is phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl and nitro;
- n is an integer of from 2 to 6 inclusive, provided that when C.sub.n H.sub.2n represents a branched alkylene chain, then at least 2 carbon atoms are present in the linear portion of the chain linking B with the piperazine nitrogen atom; and
- B is a radical having the formula ##STR69## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl, and trifluoromethyl; and
- M is a member selected from the group consisting of phenyl, phenylmethyl, mercapto, lower alkylthio, amino, lower alkylcarbonylamino, lower alkyloxycarbonylamino, and cycloalkyl having from 3 to 6 carbon atoms.
- 3. A method of producing antihistaminic or anti-anaphylactic activity in a warm-blooded animal in need of same which comprises systemic administration to said warm-blooded animal of an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of a compound having the formula ##STR70## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of phenyl, substituted phenyl and pyridinyl, wherein said substituted phenyl is phenyl having from 1 to 2 substitutents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl and nitro;
- n is an integer of from 2 to 6 inclusive, provided that when C.sub.n H.sub.2n represents a branched alkylene chain, then at least 2 carbon atoms are present in the linear portion of the chain linking B with the piperazine nitrogen atom; and B is a radical having the formula ##STR71## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl, and trifluoromethyl; and M is a member selected from the group consisting of hydrogen, lower alkyl, phenyl, phenylmethyl, mercapto, lower alkylthio, amino, lower alkylcarbonylamino, lower alkyloxycarbonylamino, and cycloalkyl having from 3 to 6 carbon atoms.
- 4. A method of producing antihistaminic or anti-anaphylactic activity in a warm-blooded animal in need of same which comprises systemic administration to said warm-blooded animal of an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of 1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1H-benzimidazole and the pharmaceutically acceptable acid addition salts thereof.
- 5. A method of producing antihistaminic or anti-anaphylactic activity in a warm-blooded animal in need of same which comprises systemic administration to said warm-blooded animal of an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of 1-[4-{4-[(4-fluorophenyl)phenylmethyl]-1-piperazinyl}butyl]-1H-benzimidazole and the pharmaceutically acceptable acid addition salts thereof.
- 6. A method of producing antihistaminic or anti-anaphylactic activity in a warm-blooded animal in need of same which comprises systemic administration to said warm-blooded animal of an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of 1-[4-{4-[bis(4-fluorophenyl)methyl]-1-piperazinyl}butyl]-1H-benzimidazole and the pharmaceutically acceptable acid addition salts thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of our copending application Ser. No. 088,703, filed Oct. 26, 1979, now abandoned, which in turn is a division of application Ser. No. 375,342, filed Feb. 6, 1978, now U.S. Pat. No. 4,200,641, which in turn is a continuation of application Ser. No. 753,062, filed Dec. 21, 1976, now abandoned, which in turn is a continuation-in-part of application Ser. No. 672,919, filed Apr. 2, 1976, now abandoned.
US Referenced Citations (2)
Divisions (1)
|
Number |
Date |
Country |
Parent |
875342 |
Feb 1978 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
88703 |
Oct 1979 |
|
Parent |
753062 |
Dec 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
672919 |
Apr 1976 |
|